Healthcare: What Was Biogen Thinking?
Industry Focus - Een podcast door The Motley Fool
Categorieën:
Biogen misses out on a huge deal that Novartis completed with AveXis. Plus, Incyte's phase 3 implosion, and what it means for immuno-oncology more broadly.
